Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30860-x ◽

2019 ◽

Vol 20 (3) ◽

pp. 408-419 ◽

Cited By ~ 89

Author(s):

Matthew Smith ◽

Chris Parker ◽

Fred Saad ◽

Kurt Miller ◽

Bertrand Tombal ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70379-0 ◽

2012 ◽

Vol 13 (10) ◽

pp. 983-992 ◽

Cited By ~ 773

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Arturo Molina ◽

Christopher J Logothetis ◽

Kim N Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70474-7 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1397-1406 ◽

Cited By ~ 208

Author(s):

Peter Hoskin ◽

Oliver Sartor ◽

Joe M O'Sullivan ◽

Dag Clement Johannessen ◽

Svein I Helle ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Subgroup Analysis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Re: Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients with Castration-Resistant Prostate Cancer and Bone Metastases: Results from a Phase 3, Double-Blind, Randomised Trial

The Journal of Urology ◽

10.1016/j.juro.2014.12.077 ◽

2015 ◽

Vol 193 (3) ◽

pp. 847-848

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Randomised Trial ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71205-7 ◽

2015 ◽

Vol 16 (2) ◽

pp. 152-160 ◽

Cited By ~ 642

Author(s):

Charles J Ryan ◽

Matthew R Smith ◽

Karim Fizazi ◽

Fred Saad ◽

Peter F A Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study

International Journal of Urology ◽

10.1111/iju.13051 ◽

2016 ◽

Vol 23 (5) ◽

pp. 404-411 ◽

Cited By ~ 11

Author(s):

Yinghao Sun ◽

Qing Zou ◽

Zhongquan Sun ◽

Changling Li ◽

Chuanjun Du ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Bridging Study

Faculty Opinions recommendation of Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718242837.793489809 ◽

2014 ◽

Author(s):

Joan Hester

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70183-4 ◽

2014 ◽

Vol 15 (7) ◽

pp. 738-746 ◽

Cited By ~ 294

Author(s):

Oliver Sartor ◽

Robert Coleman ◽

Sten Nilsson ◽

Daniel Heinrich ◽

Svein I Helle ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Randomised Trial ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2012.07.002 ◽

2013 ◽

Vol 11 (1) ◽

pp. 20-26 ◽

Cited By ~ 79

Author(s):

Sten Nilsson ◽

Lars Franzén ◽

Christopher Parker ◽

Christopher Tyrrell ◽

René Blom ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Era 223—A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and Prednisone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (Crpc)

Annals of Oncology ◽

10.1093/annonc/mdu336.50 ◽

2014 ◽

Vol 25 ◽

pp. iv278 ◽

Cited By ~ 1

Author(s):

M.R. Smith ◽

C. Parker ◽

B. Tombal ◽

K. Miller ◽

F. Saad ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Castration Resistant ◽